The most recent trial with NLY0, a glucagon-like peptide-1 receptor agonist, believed to exert anti-inflammatory effects by reducing microglial activation, did not show any improvement in PD symptoms compared to placebo, except a possible motor benefits observed in the youngest patients (McGarry et al. 2024). The gene discussed is GLP1R; the disease is Parkinson disease.